Can MSCs Treat Patients with COVID-19?
Authored by Mayasari Lim | West Coast and APAC lead for RoosterBio Amidst the scramble and panic-buying that some of us are experiencing, several treatments to combat this novel ... More
Biomanufacturing
Scalable MSC Manufacturing Matters in a Rapid Response to COVID-19
Authored by: Jon Carson, Iain Farrance, John Getz, and Jon A. Rowley, RoosterBio, Inc. On 31-December-2019, Chinese officials alerted the World Health Organization of an outbreak of pneumonia cases in ... More
What Are MSCs?
Originally Authored by Jon A. Rowley, PhD, Founder (February 15, 2014). Updated by Iain Farrance, PhD and Jon Carson, PhD (February 5, 2020) What’s in a Name? MSC is the common ... More
Quality Begins at Inception
Authored by: Kathy Williams, Vice President of Quality Assurance/Regulatory Affairs and Caitlin Hansen, Director of Quality Control RoosterBio Quality Excellence: we nurture a hard-working innovative culture where quality begins at ... More
Generating MSC-EVs With a Scalable Manufacturing System
Authored by: Katrina Adlerz, PhD, Scientist, Analytical, Process & Product Development, RoosterBio Scalability of EV Manufacturing is a Major Challenge Previously, we discussed the emergence of MSC extracellular vesicles (EVs) ... More
Advances in Clinical Translation and Scale-up of MSCs and Extracellular Vesicles at ISCT 2019
Authored by Katrina Adlerz, Ph.D., Scientist, Analytics, Product & Process Development & Josephine Lembong, Ph.D., Scientist, Analytics, Product & Process Development The 2019 International Society for Cell and Gene Therapy (ISCT) ... More
Building Effective Multi-Year Process Development Programs: Evolution of Technology Platform Decisions Based on Lot Size
Authored by Josephine Lembong, Ph.D., Scientist, Product & Process Development & Jon Rowley, Ph.D., Founder and Chief Product Officer, RoosterBio Inc. Previously, we published a blog post on estimating hMSC ... More
Building Effective Multi-Year Process Development Programs: Estimating hMSC Lot Size Ranges for Clinical Manufacturing through Commercial Demand – it is all about the assumptions
Authored by Josephine Lembong, Ph.D., Scientist, Product & Process Development & Jon A. Rowley, Ph.D., Founder and Chief Product Officer, RoosterBio Inc. Jon Rowley, RoosterBio’s Founder and Chief Product Officer, gave a talk at ... More
ISCT 2018: MSC Biomanufacturing, Bioprocessing, Scale-Up, Analytics and Exosome Production Take Center Stage
Authored by Katrina Adlerz, Ph.D. Scientist, Analytical Development, RoosterBio Inc. RoosterBio attended the International Society for Cell Therapy annual meeting, held May 2-5, 2018 in Montreal, which brought together leaders ... More
Opportunities for BioManufacturing Sciences to Accelerate Upscaled Mesenchymal Stem Cell Manufacturing Technologies
Contributed by: Timothy R. Olsen, Ph.D. – Sr. Scientist, Process and Product Development at RoosterBio Inc. After the National Institute for Standards and Technology (NIST) identified upcoming challenges in the U.S. ... More